Open AccessCardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience
Author(s) -
Giuseppiovo,
Daniela Di Lisi,
Enrico Bronte,
Francesca Macaione,
Vincenzo Accurso,
Giuseppe Badalamenti,
Gaetana Rinaldi,
Sergio Siragusa,
Salvatore Novo,
Antonio Russo
Publication year - 2020
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000505486
Subject(s) - medicine , cardiology , nilotinib , dasatinib , adverse effect , pulse wave velocity , cancer , coronary artery disease , imatinib , surgery , blood pressure , myeloid leukemia
Target therapy can cause various cardiovascular complications. The aim of this study was to evaluate the burden of cardiovascular complications related to treatment with anti-BCR-ABL tyrosine kinase inhibitors (TKIs) and to determine if there are differences between the latest- and first-generation TKIs.